Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Shares Outstanding (Weighted Average): 2019-2024

Historic Shares Outstanding (Weighted Average) for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Dec 2024 value amounting to $252.5 million.

  • Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) rose 1.24% to $255.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $255.4 million, marking a year-over-year increase of 1.24%. This contributed to the annual value of $252.5 million for FY2024, which is 0.45% up from last year.
  • As of FY2024, Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) stood at $252.5 million, which was up 0.45% from $251.4 million recorded in FY2023.
  • In the past 5 years, Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) registered a high of $257.8 million during FY2020, and its lowest value of $250.9 million during FY2022.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $251.6 million, with a median of $251.4 million in 2023.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) declined by 1.68% in 2022, and later climbed by 0.45% in 2024.
  • Yearly analysis of 5 years shows Maravai Lifesciences Holdings' Shares Outstanding (Weighted Average) stood at $257.8 million in 2020, then declined by 1.04% to $255.2 million in 2021, then decreased by 1.68% to $250.9 million in 2022, then increased by 0.21% to $251.4 million in 2023, then rose by 0.45% to $252.5 million in 2024.